The lowering of the price target from $9 to $8 by Wedbush suggests a less optimistic view on Sage Therapeutics' short-term performance. The Neutral rating indicates that the analyst does not foresee significant upside or downside, but the reduced price target may lead to a negative sentiment among investors.